Work

Frequency Of Allogeneic Stem Cell Transplant (SCT) In Patients Presenting With Newly-Diagnosed AML Or AML At Time Of First Salvage Therapy

Year: 2010

Type: article

Abstract: Allogeneic SCT is widely considered the therapy most likely to prolong survival in pts with AML in first complete remission (CR1) or relapse (REL). Questions have arisen regarding the frequency with which the procedure is undertaken in a defined population of pts presenting with newly-diagnosed AML and subsequently followed through REL and after, or in pts presenting in REL. We first analyzed 26 consecutive pts age<70 who did not have CBF AML, who were not NPM1+/FLT3-, and who achieved CR1 with at least 4 months have elapsing from presentation date.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2009.12.377